SCHEMBL6478331

SCHEMBL6478331

COC(=O)c1ccc(-c2cc3cc(C)ccc3n2C)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.62
TDP1 Q9NUW8 1/20 0.50
LMNA P02545 4/20 0.48
TP53 P04637 3/20 0.48
NPC1 O15118 3/20 0.47
RAB9A P51151 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
ATM Q13315 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
ADORA2A P29274 2/20 0.46
ADORA2B P29275 2/20 0.46
THRB P10828 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PDGFRB P09619 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13940626 0.83 KMT2A (0.59) MAPTNPC1RAB9AALDH1A1KDM4E
SCHEMBL6707155 0.83 MAPT (0.46) MAPTLMNANPC1RAB9AALDH1A1
SCHEMBL13444463 0.82 KMT2A (0.53) MAPTLMNATP53ADORA2BTHRB
SCHEMBL22004148 0.82 KMT2A (0.54) MAPTTDP1NPC1ALDH1A1KDM4E
SCHEMBL7877590 0.77 L3MBTL1 (0.72) MAPTLMNATP53ALDH1A1KDM4E
SCHEMBL10357611 0.76 CYP3A4 (0.47) MAPTNPC1L3MBTL1
SCHEMBL11686956 0.75 KMT2A (0.46) MAPTTP53KDM4ESMN1; SMN2ADORA2B
SCHEMBL18470544 0.75 MAPT (0.49) MAPTLMNATP53NPC1RAB9A
SCHEMBL6489298 0.75 KMT2A (0.46) MAPTLMNATP53NPC1RAB9A
SCHEMBL553819 0.74 MEN1 (0.54) MAPTTDP1LMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014942-A1 Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation NIPPON SHINYAKU CO., LTD. (JP) 2005-01-20 US disclosed
EP-1452525-A1 AMIDE DERIVATIVES AND DRUGS Nippon Shinyaku Co., Ltd. (JP) 2004-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014942-A1 Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation TGFBR1, TGFBR2, TGFB1 MAPT 4750/4885TDP1 4752/4885LMNA 2502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.